Clinical Trials

More documents

Recommendations

Info

❘❙❚■ Chapter 21 | Analysis of Survival DataTable 5. Selected predictors of cardiovascular death or hospitalization due to chronic heart failure (CHF)in the CHARM trial (7,599 patients) [5].Variables Coefficient Hazard ratio 95% CI P-valueAge (years) 0.04 1.04 1.03 1.05
<strong>Clinical</strong> <strong>Trials</strong>: A Practical Guide ■❚❙❘Assessing the size of treatment effect in a two-arm trialfor survival dataIn this section, we introduce some measurements of treatment effect in a two-armtrial and discuss their advantages and disadvantages.Risk difference, risk ratio, and odds ratioRisk is simply measured as the proportion of subjects who have an event ofinterest by a specific time point. The odds are the ratio of patients with an eventcompared to those without the event [5]. The risk difference or ratio and the oddsratio are sometimes used to measure the treatment effect at a specific point infollow-up when an endpoint is time to the occurrence of an event. However, thesemeasurements may be biased for the following reasons:• They are based on the assumption that all patients were followed-upto the end of the study if they had not died. In our example, not allpatients who had not died reached 48 months of follow-up dueto censoring.• Patients with censored events might not be balanced between thetwo groups.• No distinction is made between patients who die at 1 monthand those who die at 48 months.Incidence rate difference and ratioTo take different follow-up times into account, we can calculate an incidence rate,ie, the number of events divided by the number of units of time [5]. By comparingthe incidence rates between treatment groups, we can derive the incidencerate difference and ratios following the procedures described by Kirkwood andSterne [5]. For the pancreatic cancer trial data, the incidence rates are calculatedas 0.9 and 2.9 deaths per 100 person-months for the new treatment group and thestandard treatment group, respectively. The estimates of incidence rate differenceand rate ratio, together with their 95% CI and P-value, are as follows:• incidence rate difference: –2.0, 95% CI (–3.9, –0.1), P = 0.034• incidence rate ratio: 0.30, 95% CI (0.08, 0.94), P = 0.026The above results suggest that the new treatment reduces deaths by two per100 person-months, with a 95% CI of 0.1, 3.9 per 100 person-months, and that theincidence rate for patients in the new treatment group is only about 30% of theincidence rate for those in the standard treatment group.249
Page 8:
❘❙❚■ ContributorsStephen L
Page 11 and 12:
Clinical Trials: A Practical Guide
Page 13 and 14:
Page 15:
Page 19 and 20:
■■❚❙❘Chapter 1RandomizedC
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31:
Page 34 and 35:
❘❙❚■ Chapter 2 | Uncontroll
Page 36 and 37:
Page 38 and 39:
Page 41 and 42:
■■❚❙❘Chapter 3Protocol De
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
■■❚❙❘Chapter 4EndpointsAm
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
■■❚❙❘Chapter 5Patient Sel
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
■■❚❙❘Chapter 6Source and
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
■■❚❙❘Chapter 7Randomizati
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91:
Page 94 and 95:
❘❙❚■ Chapter 8 | BlindingBl
Page 96 and 97:
❘❙❚■ Chapter 8 | BlindingTh
Page 98 and 99:
❘❙❚■ Chapter 8 | BlindingAs
Page 100 and 101:
❘❙❚■ Chapter 9 | Sample Siz
Page 102 and 103:
Page 104 and 105:
Page 107:
■■❚❙❘Part IIAlternativeTr
Page 110 and 111:
❘❙❚■ Chapter 10 | Crossover
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
100
Page 120 and 121:
❘❙❚■ Chapter 11 | Factorial
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
❘❙❚■ Chapter 12 | Equivalen
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
❘❙❚■ Chapter 13 | Bioequiva
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
❘❙❚■ Chapter 14 | Noninferi
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
❘❙❚■ Chapter 15 | Cluster R
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
152
Page 172 and 173:
❘❙❚■ Chapter 16 | Multicent
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 183 and 184:
■■❚❙❘Part IIIBasics ofSta
Page 185 and 186:
■■❚❙❘Chapter 17Types of D
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
■■❚❙❘Chapter 18Significan
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216: ■■❚❙❘Chapter 19Comparison
Page 217 and 218: Clinical Trials: A Practical Guide
Page 235 and 236: ■■❚❙❘Chapter 20Comparison
Page 253 and 254: ■■❚❙❘Chapter 21Analysis o
Page 265: Clinical Trials: A Practical Guide
Page 271 and 272: ■■❚❙❘Part IVSpecial Trial
Page 273 and 274: ■■❚❙❘Chapter 22Intention-
Page 283 and 284: ■■❚❙❘Chapter 23Subgroup A
Page 291 and 292: ■■❚❙❘Chapter 24Regression
Page 305 and 306: ■■❚❙❘Chapter 25Adjustment
Page 313 and 314: ■■❚❙❘Chapter 26Confoundin
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
■■❚❙❘Chapter 27Interactio
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
■■❚❙❘Chapter 28RepeatedMe
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
■■❚❙❘Chapter 29Multiplici
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
■■❚❙❘Chapter 30Missing Da
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
■■❚❙❘Chapter 31Interim Mo
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
■■❚❙❘Chapter Part V32Repo
Page 383 and 384:
■■❚❙❘Chapter 32Overview o
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
■■❚❙❘Chapter 33Trial Prof
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
■■❚❙❘Chapter 34Presenting
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
■■❚❙❘Chapter 35Use of Tab
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
■■❚❙❘Chapter 36Use of Fig
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
■■❚❙❘Chapter 37Critical A
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
■■❚❙❘Chapter 38Meta-Analy
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
■■❚❙❘GlossaryGlossary453
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
■■❚❙❘AbbreviationsAbbrevi
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
■■❚❙❘IndexIndex467
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
show all

Clinical Trials

Create successful ePaper yourself

Delete template?

Save as template?